Alzheimers Res Ther Volume 3(2); 2011

Volume 3(2); 2011

Commentary

Selectivity to amyloid-β precursor protein cleavage provides hope against Alzheimer's

Taisuke Tomita, Philip C Wong

Alzheimers Res Ther. 2011; 3(2): 7. Published online 2011 March 11. doi: 10.1186/alzrt66

PMCID:: PMC3226269

Abstract Full Text PDF–132K

Research

Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice

Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley, Li-Ru Zhao

Alzheimers Res Ther. 2011; 3(2): 8. Published online 2011 March 15. doi: 10.1186/alzrt67

PMCID:: PMC3226270

Abstract Full Text PDF–1.3M

For debate: substituting placebo controls in long-term Alzheimer's prevention trials

René Spiegel, Manfred Berres, André R Miserez, Andreas U Monsch

Alzheimers Res Ther. 2011; 3(2): 9. Published online 2011 March 21. doi: 10.1186/alzrt68

PMCID:: PMC3226271

Abstract Full Text PDF–401K

CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques

Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen

Alzheimers Res Ther. 2011; 3(2): 12. Published online 2011 April 5. doi: 10.1186/alzrt71

PMCID:: PMC3226274

Abstract Full Text PDF–492K

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine

Alzheimers Res Ther. 2011; 3(2): 16. Published online 2011 April 19. doi: 10.1186/alzrt75

PMCID:: PMC3226277

Abstract Full Text PDF–379K Supplementary Material

Reviews

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease

Michael J Pontecorvo, Mark A Mintun

Alzheimers Res Ther. 2011; 3(2): 11. Published online 2011 March 29. doi: 10.1186/alzrt70

PMCID:: PMC3226273

Abstract Full Text PDF–194K

What can we learn from study of Alzheimer's disease in patients with Down syndrome for early-onset Alzheimer's disease in the general population?

Robyn A Wallace, Arthur J Dalton

Alzheimers Res Ther. 2011; 3(2): 13. Published online 2011 April 19. doi: 10.1186/alzrt72

PMCID:: PMC3226275

Abstract Full Text PDF–178K

Investigational drugs for the treatment of AD: what can we learn from negative trials?

Sandra A Jacobson, Marwan N Sabbagh

Alzheimers Res Ther. 2011; 3(2): 14. Published online 2011 April 15. doi: 10.1186/alzrt73

PMCID:: PMC3226276

Abstract Full Text PDF–227K

Viewpoint

Requiring an amyloid-β_1-42biomarker may improve the efficiency of a study, and simulations may help in planning studies

Suzanne B Hendrix

Alzheimers Res Ther. 2011; 3(2): 10. Published online 2011 March 28. doi: 10.1186/alzrt69

PMCID:: PMC3226272

Abstract Full Text PDF–357K

Articles from Alzheimer's Research & Therapy are provided here courtesy of
BioMed Central

PMC Canada | Copyright | Disclaimer

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's Canada Institute for Scientific and Technical Information in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers.